For the quarter ending 2025-09-30, IOBT had $2,788K increase in cash & cash equivalents over the period. -$18,482K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -8,378 | -48,638 |
| Depreciation | 61 | 125 |
| Equity-based compensation | 1,476 | 3,176 |
| Non-cash interest expense | 886 | 253 |
| Amortization of right of use lease asset | 169 | 336 |
| Foreign currency loss (gain) | 98 | -479 |
| Change in fair value of warrants | -9,846 | 2,587 |
| Prepaid expenses and other current assets | 975 | 636 |
| Other non-current assets | 13 | 882 |
| Accounts payable | 50 | 877 |
| Lease liability | -139 | -418 |
| Accrued expenses and other current liabilities | -1,671 | -152 |
| Net cash used in operating activities | -18,478 | -42,893 |
| Purchase of property and equipment | 4 | 54 |
| Net cash used in investing activities | -4 | -54 |
| Proceeds from the issuance of debt | 14,714 | 11,720 |
| Payments of debt issuance costs | 18 | 233 |
| Proceeds from issuance of common stock upon exercise of stock options | 2 | - |
| Proceeds from issuance of common stock in connection with at-the-market program, net of issuance costs of 134 | 6,572 | - |
| Net cash provided by financing activities | 21,270 | 11,487 |
| Net decrease in cash, cash equivalents and restricted cash | 2,788 | -31,460 |
| Effect of exchange rate changes on cash | -695 | - |
| Cash and cash equivalents at beginning of period | 60,299 | - |
| Cash and cash equivalents at end of period | 30,932 | - |
IO Biotech, Inc. (IOBT)
IO Biotech, Inc. (IOBT)